News

Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration of response in patients with advanced biliary tract cancer.

Significant Ki-67 protein suppression in HR-positive, HER2-negative breast cancer was seen among patients treated with lasofoxifene.

The FDA recently approved a phase 2 clinical trial to investigate the efficacy of leronlimab in patients with relapsed or refractory microsatellite-stable metastatic colorectal cancer.

Susan L. Slager, PhD, discussed the etiology and inherited genetic factors that are associated with the risk of chronic lymphocytic leukemia.

Prithviraj Bose, MD, discusses the most critical adverse effects seen with each of the 4 approved JAK inhibitors for the treatment of myeloproliferative neoplasms.

The FDA has extended its review of zenocutuzumab's in NRG1+ NSCLC and PDAC to February 2025, with efficacy and safety data from the eNRGy trial supporting the application.

Casdatifan showed notable clinical activity and an acceptable safety profile in treating patients with metastatic clear cell renal cell carcinoma.

Despite regulatory challenges from the FDA, odronextamab has received European approval for the treatment of patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma following 2 prior treatments.

In an interview, Colton Ladbury, MD, discussed new insights from a study and expanded on total marrow irradiation’s potential to transform transplant conditioning.

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed following treatment with a type I JAK2 inhibitor.

Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.

Domenica Lorusso, MD, PhD, discussed the KEYNOTE-A18 trial, its findings, and implications for oncologists.

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

The FDA has lifted clinical holds on trials of zevor-cel, satri-cel, and CT071, and trials will now resume in the US.

Hamlet Gasoyan, MD, discussed the implications of a multiple myeloma study’s findings and their potential impact on clinical practice and patient outcomes.

Aumolertinib showed improved PFS in NSCLC and ivonescimab outperforms pembrolizumab in advanced cases. Plus, insights into CAR T-cell therapy and its associated AEs are discussed in relapsed multiple myeloma.

Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs trastuzumab emtansine in the context of HER2-positive breast cancer with brain metastases.

A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute myeloid leukemia did not achieve the primary end point of improved event-free survival.

David Sallman, MD, discussed the challenges and new studies of high-risk myelodysplastic syndrome therapies.

The FDA recently approved the combination of inavolisib, fulvestrant, and palbociclib in this patient population.

Mark R. Litzow, MD, discusses the findings from the ECOG-ACRIN E1910 trial which evaluated blinatumomab added to chemotherapy vs chemotherapy alone in B-cell precursor acute lymphoblastic leukemia.

Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of tucatinib, trastuzumab, and capecitabine in HER2-positive breast cancer with leptomeningeal metastasis.

Binod Dhakal, MD, MS, discusses the key takeaways from the CARTITUDE-4 trial which were presented at the 2024 International Myeloma Society Annual Meeting.

Here is a look back on all the FDA happenings from the month of October 2024.

In an interview with Targeted Oncology, Josep Maria Ribera, MD, PhD, discussed the evolving treatment protocols for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Erika Hamilton, MD, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive breast cancer.

Nazli Dizman, MD, discussed the current measures for enforcing ASCO’s language of respect guidelines in the renal cell carcinoma space.

Mark A. Lewis, MD, discusses dostarlimab-gxly and how experts can best counsel patients with locally advanced mismatch repair-deficient rectal cancer about the potential for long-term disease control with this agent.

In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.

Noah S. Kalman, MD, MBA, highlighted advancements in thyroid cancer treatment, emphasizing personalized therapies, molecular testing, and optimizing traditional approaches.